Stock 002275 GUILIN SANJIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Guilin Sanjin Pharmaceutical Co., Ltd.

Equities

002275

CNE100000DY9

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 20/05/2024 BST 		5-day change 1st Jan Change
14.42 CNY -0.62% Intraday chart for Guilin Sanjin Pharmaceutical Co., Ltd. -3.80% -0.48%
04-26 Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 CI
04-25 Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Implements Profit Distribution plan for the Third Quarter of 2023, Payable on 27 November 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves 2023 Third Quarter Profit Distribution Plan
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Third Quarter Dividend for 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 31, 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Dividend for the Third Quarter of 2022
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Third Quarter of 2022
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO
MT
Biocytogen Pharmaceuticals Launches $70 Million Hong Kong IPO
MT
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on 30 May 2022
CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002275 Stock
  4. News Guilin Sanjin Pharmaceutical Co., Ltd.
  5. Highlights